NewAmsterdam Pharma Company N.V. (NAMS) is a Biotechnology company in the Healthcare sector, currently trading at $34.44. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is NAMS = $47 (+37% upside).
Valuation: NAMS trades at a trailing Price-to-Earnings (P/E) of -19.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.7.
Financials: revenue is $23M, +39.9%/yr average growth. Net income is $204M (loss), growing at -252.7%/yr. Net profit margin is -905.7% (negative). Gross margin is 99.7% (-0.3 pp trend).
Balance sheet: total debt is $202,000 against $683M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 7.88 (strong liquidity). Debt-to-assets is 0%. Total assets: $769M.
Analyst outlook: 9 / 10 analysts rate NAMS as buy (90%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
